Legionella bacteria found at London's Victoria hospital, officials say
Testing of Victoria Hospital's cooling towers has returned positive results for legionella bacteria as local health officials investigate an ongoing Legionnaires' disease outbreak in the city, according to officials at London Health Sciences Centre (LHSC).
LHSC officials say two samples were taken from the hospital's cooling towers and air-conditioning systems on July 16 and 17.
It followed confirmation from the Middlesex-London Health Unit (MLHU) that the Victoria campus fell within a six-kilometre radius where most cases in the outbreak had been found.
In a statement on Wednesday, southwestern Ontario's largest hospital network revealed that the cooling tower samples came back positive for legionella bacteria on an initial screening test.
"More testing is now underway to find out if it matches the strain causing the community outbreak," the statement said. "Those results will take approximately three weeks. We want to be clear: this does not mean Victoria Hospital is the source of the community outbreak."
LHSC said the risk to patients, staff and visitors remains very low, but individuals who are older, have lung problems or are immunocompromised (have a weak immune system) are at greater risk of serious infection.
The outbreak, declared on July 8, has impacted at least 69 people, according to the latest numbers from the MLHU. Two people have since died, and source of the outbreak has not yet been determined.
In an interview, Dr, Nadim Khalil, site lead of infection prevention and control at Children's Hospital, said no hospital-acquired cases had presented to LHSC.
"The public health unit has been testing different samples to see what could be the source of it, and because of our location at Victoria Hospital, we got tested. We have sent samples from our University Hospital as well, which is going to be much more lower-risk," he said.
He added that cooling towers are, "more to help evaporate some of the temperature that's in the building, but not circulate into the air conditioning system."
Legionnaires' disease is caused by legionella bacteria, naturally found in water sources like hot tubs, cooling towers, hot water tanks, large plumbing systems or parts of air-conditioning systems.
Legionella is not transmitted from person to person. If the bacteria are aerosolized or misted into the air (via wind or fans), people may inhale the bacteria and become unwell. Most people exposed to legionella don't get ill, but some may experience Pontiac fever, a mild, flu-like illness that commonly resolves itself.
"The challenging thing for us is the cooling towers have to be present to help cool the building, especially during summer, (but) the waters can be a bit stagnant in it because it's not circulating with the rest of the building," Khalil said.
"We do have our policies to get the water tested per provincial guidelines as well as treatment. We treat the water twice a year. When we did hear about the outbreak, we treated the water an extra time."
Khalil says LHSC treated the water a fourth time to be safe, but says the results came back positive, prompting a chemical cleaning of the towers, followed by a thorough systematic clean.
One challenge, he says, is that legionella can be slow to develop — upwards of two weeks on an agar plate.
"So they do additional DNA amplification, what we call PCR, to help see if there's any residual bacteria, and that's what came back positive. What that means is still unclear," he said.
"We do know a lot of water, if it's going to be tested, can be positive, and we do know, talking to the health unit, almost 80 per cent of samples they've had have tested positive."
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


CTV News
4 hours ago
- CTV News
Knee surgery changes course of common knee problem, according to local researchers
London-based study shows that a specialized knee surgery can prevent knee replacement. CTV's Reta Ismail has more. Researchers at Western have made significant progress treating a common knee issue, allowing some to avoid knee replacement. People suffering with knee osteoarthritis, a condition which brings pain, stiffness and sometimes the need for joint replacement surgery, can undergo a surgical operation called high tibial osteotomy. 'So in the surgery, they'll take that maligned limb, so that bowed limb, and actually straighten it to shift loads away from the most damaged compartment of the knee,' said Dr. Trevor Birmingham, professor and Canada research chair in musculoskeletal rehabilitation in Western's faculty of health sciences. The study is led by researchers at Western University and the Fowler Kennedy Sport Medicine Clinic. A two-year clinical trial followed 145 patients and compared those who had HTO and non-surgical therapy with those who only had therapy. The results showed that HTO slowed joint damage, reduced pain and improved movement. This is the first real evidence that a treatment can cand the course of osteoarthritis. The surgery is less common than joint replacement, but the researchers believe it needs more attention to help people in their 50s with specific alignment issues. - With files from CTV's Reta Ismail

Cision Canada
19 hours ago
- Cision Canada
Stay Home Forever Inc. Appoints Dane Clarke as First President and Chief Operating Officer
Industry leader brings culture-driven approach to Ontario-based homecare provider Stay Home Forever Inc. as he steps into the newly created role of President and Chief Operating Officer. TORONTO, July 29, 2025 /CNW/ - Stay Home Forever Inc. ("SHF"), a leading provider of private homecare services across Ontario, today announced the appointment of Dane Clarke as the President and Chief Operating Officer, effective immediately. To support its next phase of growth, SHF has created this new role, appointing Dane to lead operations and strategy while driving immediate impact with a culture-driven mission. Dane brings over 20 years of executive experience in healthcare operations, workforce strategy, and organizational growth. He has held leadership roles at CBI Health Group, Sinai Health Systems, and WSIB, leading initiatives that improved outcomes and expanded service delivery. Dane also played a key role in driving system-level change and navigating crisis response for healthcare organizations, including Ontario Health Teams (OHTs), co-chairing the Home Care Table during the covid-19 pandemic, and a key contributor to various initiatives and stakeholder engagements with Ontario Health. He attended the Ivey School of Business, reinforcing his ability to lead transformational change and cross-sector healthcare initiatives. "We are thrilled to welcome Dane to the SHF family," said Saye Sathiyakumar, CEO of Stay Home Forever Inc. "His proven leadership, deep industry knowledge, and passion for compassionate care align perfectly with our values. Dane's vision and operational expertise will be instrumental as we continue to scale our services and innovate in the homecare sector." "Joining Stay Home Forever is both a professional and personal calling," said Dane. "I look forward to working closely with Saye and the SHF team to strengthen our foundation, expand our services, and meet the growing need for culturally responsive care in Ontario." Dane's appointment reflects Stay Home Forever's identity as a proudly minority-owned company. As a second-generation Canadian, his personal experiences bring critical insight to a sector where much of the workforce shares similar backgrounds. His leadership helps ensure that the voices of underrepresented communities are reflected at every level of care. Stay Home Forever Inc. has earned a reputation for delivering personalized and client-centred care rooted in the belief that everyone deserves to live with dignity, comfort and connection. With Dane's leadership, SHF will continue to expand its tailored services and advance culturally responsive care for families across Ontario. About Stay Home Forever Inc. Founded in 2019, Stay Home Forever Inc. is a leading provider of private homecare services in Ontario. The company offers a comprehensive range of services - including personal care, companionship, nursing, and specialized support - all designed to promote independence and enhance quality of life. SHF is committed to delivering compassionate, reliable, and culturally appropriate care that meets the highest standards of excellence.

National Post
20 hours ago
- National Post
Bausch + Lomb Announces Publication of Phase 3 Data on LUMIFY® Preservative Free Redness Reliever Eye Drops
Article content Phase 3 data show Bausch + Lomb's LUMIFY Preservative Free eye drops are as safe and effective as the original LUMIFY in reducing ocular redness The multicenter study with 380 participants confirmed that LUMIFY Preservative Free eye drops are non-inferior in efficacy to the original LUMIFY and have a favorable safety profile, offering an effective preservative-free option for sensitive eyes LUMIFY delivers noticeable results in one minute, lasts up to eight hours and is the No. 1 doctor-recommended redness reliever brand; more info at Article content VAUGHAN, Ontario — Bausch + Lomb Corporation (NYSE/TSX: BLCO), a leading global eye health company dedicated to helping people see better to live better, today announced Ophthalmology and Therapy has published results from a phase 3 study which assessed the efficacy and safety of LUMIFY Preservative Free redness reliever eye drops compared to LUMIFY redness reliever eye drops for reducing ocular redness. Article content 'Since launching in 2018, LUMIFY has been the No. 1 doctor-recommended redness reliever brand, known for delivering noticeable results in one minute and lasting up to eight hours,' 1 said John Ferris, president, Consumer, Bausch + Lomb. 'This study demonstrates that our new LUMIFY Preservative Free eye drops reduce redness quickly and are just as safe and effective as the original LUMIFY, providing a needed option for patients with eye sensitivities.' Article content In the randomized, active-controlled, multicenter study, 380 participants with ocular redness received either LUMIFY Preservative Free or LUMIFY, administered as a single drop four times daily for four weeks. The primary objective was to demonstrate that LUMIFY Preservative Free is non-inferior to LUMIFY in reducing ocular redness. The primary efficacy endpoint was investigator-assessed ocular redness score at eight timepoints from five-minutes to 240-minutes after drop administration on day one. The secondary objective of the study was to compare the safety of LUMIFY Preservative Free and LUMIFY. Article content The study met its primary objective, confirming that LUMIFY Preservative Free is statistically non-inferior to LUMIFY in reducing ocular redness in adults. A day one analysis of all 11 time points (one minute to 480 minutes post-administration) further supported these findings; and additional secondary efficacy endpoint data from one minute, 360 minutes and 480 minutes post-administration demonstrated that LUMIFY Preservative Free performs similarly to LUMIFY. The overall safety profile of LUMIFY Preservative Free was favorable and comparable to LUMIFY, and the occurrence of ocular treatment-emergent adverse events was similar in both treatment groups. In this clinical trial, LUMIFY Preservative Free demonstrated to have a low incidence of side effects, like rebound redness and loss of efficacy over time, when used as directed. Article content 'The results show that LUMIFY Preservative Free is a well-tolerated alternative option for consumers with ocular redness who have sensitivities to preservatives or are at increased risk of ocular surface disease,' said Melissa Toyos, MD, and partner, Toyos Clinic, Nashville, TN. Article content About the LUMIFY Brand Article content The LUMIFY brand began in 2018 with the U.S. launch of LUMIFY redness reliever eye drops. Before LUMIFY, redness relievers relied on the same ingredients for decades and were associated with well-known side effects. LUMIFY and LUMIFY Preservative Free are the only over-the-counter redness relievers formulated with low-dose brimonidine tartrate 0.025% that selectively target eye redness and offer excellent results with a lower risk of rebound redness and loss of efficacy when used as directed. In 2023, Bausch + Lomb introduced LUMIFY EYE ILLUMINATIONS™, a line of specialty eye care products specifically developed for the sensitive area around the eyes. In June 2025, Bausch + Lomb launched LUMIFY Preservative Free eye drops in the U.S. For more information on the LUMIFY brand, visit Article content Bausch + Lomb is dedicated to protecting and enhancing the gift of sight for millions of people around the world – from birth through every phase of life. Its comprehensive portfolio of approximately 400 products includes contact lenses, lens care products, eye care products, ophthalmic pharmaceuticals, over-the-counter products and ophthalmic surgical devices and instruments. Founded in 1853, Bausch + Lomb has a significant global research and development, manufacturing and commercial footprint with approximately 13,500 employees and a presence in approximately 100 countries. Bausch + Lomb is headquartered in Vaughan, Ontario, with corporate offices in Bridgewater, New Jersey. For more information, visit Article content Facebook Article content , Article content Instagram Article content , Article content LinkedIn Article content , Article content X Article content and Article content YouTube Article content . Article content References Article content ©2025 Bausch + Lomb. Article content Article content Article content Article content Article content Article content Contacts Article content Media Contact: Article content Article content Kristy Marks Article content Article content Article content